Jones R J
Johns Hopkins Oncology Center, Baltimore, Maryland.
Curr Opin Oncol. 1991 Apr;3(2):234-7. doi: 10.1097/00001622-199104000-00002.
Autologous bone marrow transplantation (BMT) has become effective therapy for high-risk hematologic leukemias with long-term disease-free survivals and apparent cure in a substantial fraction of patients with relapsed aggressive non-Hodgkin's lymphoma, relapsed Hodgkin's disease, and the acute leukemias. Preliminary reports suggest autologous BMT may also be useful treatment for low-grade non-Hodgkin's lymphomas, chronic myelogenous leukemia, and multiple myeloma. Recent studies have begun to address the role autologous BMT should play in these diseases, especially relative to conventional-dose therapy and allogeneic BMT. Relapse remains the major cause for failure following autologous BMT. Novel approaches that can increase the antitumor effect of this treatment without increasing toxicity are being investigated.
自体骨髓移植（BMT）已成为治疗高危血液系统白血病的有效方法，可使相当一部分复发的侵袭性非霍奇金淋巴瘤、复发性霍奇金病和急性白血病患者实现长期无病生存并明显治愈。初步报告表明，自体BMT也可能是治疗低度非霍奇金淋巴瘤、慢性粒细胞白血病和多发性骨髓瘤的有效方法。最近的研究已开始探讨自体BMT在这些疾病中应发挥的作用，尤其是相对于传统剂量疗法和异基因BMT而言。复发仍然是自体BMT治疗失败的主要原因。目前正在研究能够在不增加毒性的情况下增强这种治疗抗肿瘤效果的新方法。
